Showcasing a Scalable European Biotech Ecosystem
Team Nice Côte d’Azur will participate in BIO-Europe Spring 2026 from March 23-25 in Lisbon, represented by Sana Bouyahia, Head of Project Development Health & Sports. The participation aims to showcase the region’s biotech innovation capabilities and explore partnership opportunities with international players.
A Dynamic Ecosystem Where Academic Excellence Meets Emerging Ventures
The French Riviera has built a robust translational research environment anchored by Nice University Hospital, which delivers 920 publications annually and holds 28 active patents across 8 European projects.
This foundation generates high-impact academic spinoffs that are attracting attention across European biotech markets.
DimiCare, a spinoff from Inserm/CNRS/Université Côte d’Azur, is developing precision antibiotics against resistant bacteria and was recently recognized as an i-Lab 2025 winner.
Roca Therapeutics, emerging from Université de Nice and SATT Sud Est, secured the first EMA recognition of radiation maculopathy as a distinct indication.
ExAdEx-Innov is advancing human tissue models for pharmaceutical and dermocosmetic applications, addressing limitations of traditional testing methods.
The ecosystem benefits from strategic support through Eurobiomed, a regional cluster that mobilized €302M for its members in 2025, combining academic strengths from Université Côte d’Azur, CNRS, Inserm, Inria, and INRAE with AI expertise through 3IA Côte d’Azur.
A Strategic European Gateway for International Life Sciences Companies
Recent market entries demonstrate growing international interest in the region as a European entry point.
Circum Life Sciences structured its Euro-Mediterranean operations with headquarters and R&D in Nice, manufacturing in Tunisia, and commercial operations in Zurich.
SunWaves MedTech established its European base in the region for AI-powered remote patient monitoring.
Companies benefit from comprehensive business development support infrastructure. Beyond the Eurobiomed cluster’s €302M in mobilized resources (€142M public funding, €160M private capital), the territory offers Bpifrance innovation diagnostics and IP strategy programs subsidized at 50%, established incubators including TechForward, French Tech, and Hub de l’Innovation, mentoring networks through Réseau Entreprendre and Initiative France, and direct international connectivity through Nice Côte d’Azur Airport.
The region provides scalable infrastructure, cross-border reach, and proven pathways to European commercialization.
National-Scale Programs Seeking International Collaboration
Nice Côte d’Azur operates three major France 2030 programs open for international partnerships.
IHU RespirERA, a nationally designated institute for respiratory disease innovation, leads France’s lung cancer screening information system under INCa mandate.
RHU Rebone (€24.6M) advances 3D bone reconstruction through mixed reality and AI. Skin Institute, scheduled to open in 2027, will anchor digital dermatology innovation nationally.
Partnership mechanisms include PUI Medinnov funding for prototyping collaborations, translational capabilities at Nice University Hospital (130,000 m² research and clinical space, 28 active patents), and manufacturing capacity through Circum Life Sciences with Euro-Mediterranean operations and ISO 7 cleanroom facilities.
These programs actively seek research collaboration, technology transfer, and co-development partnerships with international players, positioning Nice Côte d’Azur as infrastructure for cross-border innovation.
Schedule a Meeting in Lisbon
Companies and investors interested in exploring partnership opportunities, European market entry strategies, or collaborative research projects can schedule a meeting with Sana Bouyahia during BIO-Europe Spring 2026.
